The theme for ACannabis 2023 was Growing The Industry Through Research, Collaboration and Innovation. Dive back in to any session with our video library.
Session List – Day 1
- Session 1 – Opening & Welcome
- Session 2 – Trends and opportunities for medical cannabis
- Session 3 – Future trends in medicinal cannabis regulation around the globe
- Session 4 – In conversation with the Australian regulators
- Session 5 – Positioning the medicinal cannabis sector for success
- Session 6 – Future state of TGO 93 Panel: An in-depth look at the TGO 93 changes that are effective 1 July 2023 with particular focus on GMP Import changes and are importers ready?
- Session 7 – Navigating medicinal cannabis challenges
- Session 8 – Fireside chat with Dr Richard Di Natale, Reflections on Australia’s medicinal cannabis journey, role of evidence/education in expanding access and future directions
- Session 9 – Emerging researchers showcase
- Session 10 – Closing Comments Day 1
Session List – Day 2
- Session 11 – Welcome & Keynote address
- Session 12 – Industry and market outlook
- Session 13 – Partnering for success in the medicinal cannabis industry
- Session 14 – Best-practices for medicinal cannabis prescribers & new education tools for healthcare practitioners
- Session 15 – Keynote address – John Easterling, Launch of the Olivia Newton-John Service to Industry Award
- Session 16 – Showcasing R&D and innovation – from plant to patient
- Session 17 – Fireside chat with Cameron Scadding, How to achieve success while being ethical & legitimate
- Session 18 – Wrap Up & Closing Comments
Supplementary Video
Speaker Presentations – Day 1
Session 1 – Opening & Welcome
MC: Nathan Davis, Executive Director, MedReleaf Australia
MCIA Chair, Mr Peter Crock and
The Hon Ged Kearney MP, Federal Member for Cooper, Assistant Minister for Health and Aged Care
Session 2 – Trends and opportunities for medical cannabis
Trends and international opportunities for medicinal cannabis and cannabinoid development. Session sponsored by ARC Research Hub for Medicinal Agriculture.
Moderator
- Peter Crock, Chair, MCIA
Keynote
- Hunter Land, Vice President, Translational Research, Biopharmaceutical Research Company
Session 3 – Future trends in medicinal cannabis regulation around the globe
A look at what’s happening in cannabis regulation in key countries
Moderator
- Rosemary Richards, MCIA
Panellists
- Sally King, Executive Director, New Zealand Medicinal Cannabis Council
- Martin Woodbridge, Advisor, Bedrocan
- Jacob Vogel, Syqe
Session 4 – In conversation with the Australian regulators
Fireside Chat around the Australian regulatory landscape, future changes with
Moderator
- Donna Edman, Astute Advocacy
Panellists
- Adjunct Professor Robyn Langham, Chief Medical Advisor, TGA and
- Danielle Chifley, Director, Medicinal Cannabis, ODC
Session 5 – Positioning the medicinal cannabis sector for success
Moderator
- Jo Patterson, CEO, BOD Australia and MCIA Director
Panellists
- Patty Holmes, Holmes Wilson
- Peter Koetsier, CEO, Cann Group
- Tim Evans, Private Client Adviser, Morgans Financial Limited
- Oliver Zugel, Founder and CEO, FoliuMed
Session 6 – Future state of TGO 93 Panel
An in-depth look at the TGO 93 changes that are effective 1 July 2023 with particular focus on GMP Import changes and are importers ready?
Moderator
- Patty Holmes, Director, Holmes and Wilson
Panellists
- Jenny Burnett, Assistant Secretary – Manufacturing Quality Branch (MQB), Department of Health & Aged Care
- Steve Notaro, Head of Legal and Regulatory Affairs, Cann Group
- Gordon Chan, Quality Operations and Regulatory Affairs , MedReleaf Australia
- Clare Barker, Consultant
- Oliver Zugel, Founder and CEO, FoliuMed
Session 7 – Navigating medicinal cannabis challenges
A series of presentations from industry leaders
Moderator
- Rosemary Richards, MCIA
Presenters
- Adam Benjamin, CEO, Standard Botanic
The size of the opportunity for new Australian cannabis cultivators is almost exceeded by the size of the hurdles - Kyle Hunt, CEO and Founder, Health Care Providers Association
Obtaining a medicinal cannabis license and maintaining SOP’s - Nick Owen, Founder and CEO, Nucleotrace
A new platform for securing cannabis supply chains
Session 8 – Fireside chat with Dr Richard Di Natale
Moderator
- Martin Lane, Co Founder, Cannabiz
Speaker
- Dr Richard Di Natale
Reflections on Australia’s medicinal cannabis journey, role of evidence/education in expanding access and future directions
Session 9 – Emerging researchers showcase
Moderators
- Professor Iain McGregor, Professor of Psychopharmacology & Academic Director – Lambert Initiative for Cannabinoid Therapeutics, University of Sydney
- Dr Veronica Borrett, Senior Director, ARC Research Hub for Medicinal Agriculture
Presenters
- Laura Steel, ARC MedAG Hub, La Trobe University
The investigation of flowering time in cannabis sativa - Dr Cilla Zhou, Lambert Initiative, University of Sydney
Surveys and recruitment strategies at the Lambert Initiative - John Laws, University of Adelaide
The neurological bioactivity of cannabis prevalent terpenes: implications for medical cannabis formulations
Dr Llew Mills, Discipline of Addiction Medicine, University of Sydney
The cannabis as medicine surveys (CAMS): The evolution of medical cannabis use in Australia following deregulation - Matthew Nolan, Southern Cross University
Cannabis sativa, a model species for glandular trichome research
Dr Danielle McCartney, Lambert Initiative, University of Sydney
The effects of CBD and THC on cognitive function and driving performance - Dr Mulu Oli, ARC MedAG Hub, La Trobe University
Towards genomics-assisted improvement of glandular trichome productivity in Cannabis sativa - Dr Adam Ametovski, Lambert Initiative, University of Sydney
Cannabinoid synthesis: An overview of the medicinal chemistry program at The Lambert Initiative - Dr Martin O’Brien, ARC MedAG Hub, La Trobe University
The Use of tissue culture into a commercial production line, the “hows” to get there - Dr Anastasia Suraev, Lambert Initiative, University of Sydney
Emerging insights into the role of cannabinoids in sleep
Session 10 – Closing Comments Day 1
Speaker Presentations – Day 2
Session 11 – Welcome
MC: Nathan Davis, Executive Director, MedReleaf Australia
Peter Crock, Chair, MCIA
Councillor Elizabeth Mary Doidge, City of Melbourne
Session 11 – Keynote Address
Keynote Address from Fiona Patten MP
Session 12 – Industry and market outlook – John Penington
A look into the industry and market outlook, both here in Australia and overseas
Presenter:
- John Ryan, CEO, Penington Institute Findings from the Penington Institute Cannabis Report
Session 12 – Industry and market outlook – Andre Jerome
Presenter:
- Andre Jerome, EVP, Global Business Development, Aurora Global market opportunities
Session 13 – Partnering for success in the medicinal cannabis industry
Moderator:
- Andrew Dowling, AltMed
Panel:
- Tyson Craig, Head of Business Development Wholesale Commercial, Greenship
- Aspa Dukas, Pharmacist and Founder, Dukasa Compounding
- Tommy Huppert, Founder and CEO, Cannatrek
- Mitchell Kurz, Co Founder, Phytoca Maverick Weller, CEO, GreenHaus Australia
- Melinda Thompson, SourceCertain
Session 14 – Best-practices for medicinal cannabis prescribers & new education tools for healthcare practitioners
Moderator:
- Carol Ireland, CEO, Epilepsy Action Australia
Panel:
- Dr Orit Holtzman, Co Founder and Director, Functional & Cannabinoid Medicine Practitioner, Leura Wellness
- Stephane Kain, Service Development Manager, Epilepsy Action Australia
- Dr James Stewart
- Hugh Tait, Medical Services & Operations Manager, MedReleaf Australia
Session 15 – Keynote address – John Easterling, Launch of the Olivia Newton-John Service to Industry Award
Moderator
- Peter Crock, Chair, MCIA
Keynote speaker
- John Easterling – Cannabis in Australia. What’s next
Session 16 – Showcasing R&D and innovation – from plant to patient
An in-depth look at current status of plant research, the Endocannabinoid system, clinical trials and new medicine opportunities
Moderator:
Dr Peter Duggan, Senior Principal Research Scientist, CSIRO
Presenters:
- Associate Professor Monika S. Doblin, Research Director, ARC ITRH for Medicinal Agriculture, La Trobe University
Overview of the cannabis research landscape in Australia - Matt Hayes, PhD, Science Director, Triffid BioScience
Cannabis genetics: status, risks and management for commercial production & breeding - Dr Elizabeth Cairns, Research Fellow, Lambert Initiative for Cannabinoid Therapeutics, University of Sydney
Preclincial models of disease & endocannabinoid system - Dr Paul Wynne, Medicines Manufacturing Innovations Centre, Monash University
From plant to patient – the drive for novelty in processing, purification, and formulation of cannabinoids - Dr Amie Hayley, Rebecca L. Cooper Al and Val Rosenstrauss Fellow, Centre for Human Psychopharmacology, Swinburne University of Technology
Driving trials/impairment detection and policy solutions
Session 17 – Fireside chat with Cameron Scadding
How to achieve success while being ethical and legitimate
Moderator
- Nathan Davis, Executive Director, MedReleaf Australia
Speaker
- Cameron Scadding, CEO and Managing Director, Source Certain
Session 18 – Wrap Up & Closing Comments
Supplementary Video
Dr Kerryn Phelps, Hemp CRC
Role of evidence in expanding access to medicinal cannabis and building sustainable industries